inpha-20220630
错误Jun 30, 20222022Q2000159859912-3100015985992022-01-012022-06-3000015985992022-06-30ISO4217:欧元00015985992021-12-3100015985992021-01-012021-06-30Xbrli:共享ISO4217:欧元Xbrli:共享00015985992020-12-3100015985992021-06-300001598599IFRS-FULL:普通共享成员IFRS-Full:IssuedCapitalMembers2020-12-310001598599IFRS-Full:IssuedCapitalMembersIFRS-Full:首选项共享成员2020-12-310001598599IFRS-Full:IssuedCapitalMembers2020-12-310001598599IFRS-Full:SharePremiumMembers2020-12-310001598599Ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2020-12-310001598599IFRS-FULL:其他保留成员2020-12-310001598599Ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2020-12-310001598599Ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2021-01-012021-06-300001598599IFRS-FULL:其他保留成员2021-01-012021-06-300001598599Ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2021-01-012021-06-300001598599IFRS-FULL:普通共享成员IFRS-Full:IssuedCapitalMembers2021-01-012021-06-300001598599IFRS-Full:IssuedCapitalMembersIFRS-Full:首选项共享成员2021-01-012021-06-300001598599IFRS-Full:IssuedCapitalMembers2021-01-012021-06-300001598599IFRS-Full:SharePremiumMembers2021-01-012021-06-300001598599IFRS-FULL:普通共享成员IFRS-Full:IssuedCapitalMembers2021-06-300001598599IFRS-Full:IssuedCapitalMembersIFRS-Full:首选项共享成员2021-06-300001598599IFRS-Full:IssuedCapitalMembers2021-06-300001598599IFRS-Full:SharePremiumMembers2021-06-300001598599Ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2021-06-300001598599IFRS-FULL:其他保留成员2021-06-300001598599Ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2021-06-300001598599IFRS-FULL:普通共享成员IFRS-Full:IssuedCapitalMembers2021-12-310001598599IFRS-Full:IssuedCapitalMembersIFRS-Full:首选项共享成员2021-12-310001598599IFRS-Full:IssuedCapitalMembers2021-12-310001598599IFRS-Full:SharePremiumMembers2021-12-310001598599Ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2021-12-310001598599IFRS-FULL:其他保留成员2021-12-310001598599Ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2021-12-310001598599Ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2022-01-012022-06-300001598599IFRS-FULL:其他保留成员2022-01-012022-06-300001598599Ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2022-01-012022-06-300001598599IFRS-FULL:普通共享成员IFRS-Full:IssuedCapitalMembers2022-01-012022-06-300001598599IFRS-Full:IssuedCapitalMembers2022-01-012022-06-300001598599IFRS-Full:SharePremiumMembers2022-01-012022-06-300001598599IFRS-FULL:普通共享成员IFRS-Full:IssuedCapitalMembers2022-06-300001598599IFRS-Full:IssuedCapitalMembersIFRS-Full:首选项共享成员2022-06-300001598599IFRS-Full:IssuedCapitalMembers2022-06-300001598599IFRS-Full:SharePremiumMembers2022-06-300001598599Ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2022-06-300001598599IFRS-FULL:其他保留成员2022-06-300001598599Ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2022-06-30Inpha:子公司Inpha:员工0001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMember2022-06-172022-06-17ISO 4217:美元0001598599Inpha:A2018AstraZenecaIPH5201协议成员2022-06-012022-06-010001598599Inpha:重大里程碑付款已收到成员Inpha:A2018AstraZenecaIPH5201协议成员2022-08-022022-08-020001598599Inpha:IPH43IPH25IPH26AndIPH62WithAstraZenecaMember2022-06-30Inpha:程序0001598599Inpha:IPH43IPH25IPH26AndIPH62WithAstraZenecaMember2022-01-012022-06-300001598599Inpha:AgreementRelatedToIPH6101WithSanofiMember2022-01-012022-06-30Xbrli:纯00015985992021-01-012021-12-310001598599Inpha:SICAVMember2022-06-300001598599SRT:最小成员数Inpha:SICAVAndMutualFundsMember2022-06-30Utr:费率0001598599SRT:最大成员数Inpha:SICAVAndMutualFundsMember2022-06-300001598599Inpha:CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember2022-06-300001598599Inpha:CashCashEquivalentsAndFinancialAssetsDenominatedInUSDollarsMember2021-12-310001598599Inpha:A2018AstraZenecaIPH5201协议成员2022-06-300001598599Inpha:AgreementRelatedToIPH6101WithSanofiMember2022-06-300001598599IFRS-Full:许可证成员2020-12-310001598599IFRS-Full:其他无形资产成员2020-12-310001598599Ifrs-full:IntangibleAssetsUnderDevelopmentMember2020-12-310001598599IFRS-Full:许可证成员2021-01-012021-06-300001598599IFRS-Full:其他无形资产成员2021-01-012021-06-300001598599Ifrs-full:IntangibleAssetsUnderDevelopmentMember2021-01-012021-06-300001598599IFRS-Full:许可证成员2021-06-300001598599IFRS-Full:其他无形资产成员2021-06-300001598599Ifrs-full:IntangibleAssetsUnderDevelopmentMember2021-06-300001598599IFRS-Full:许可证成员2021-12-310001598599IFRS-Full:其他无形资产成员2021-12-310001598599Ifrs-full:IntangibleAssetsUnderDevelopmentMember2021-12-310001598599IFRS-Full:许可证成员2022-01-012022-06-300001598599IFRS-Full:其他无形资产成员2022-01-012022-06-300001598599Ifrs-full:IntangibleAssetsUnderDevelopmentMember2022-01-012022-06-300001598599IFRS-Full:许可证成员2022-06-300001598599IFRS-Full:其他无形资产成员2022-06-300001598599Ifrs-full:IntangibleAssetsUnderDevelopmentMember2022-06-300001598599Inpha:MonalizumabGonementMember2022-01-012022-06-300001598599Inpha:MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember2022-06-300001598599Inpha:MonalizumabRightsUnderThe2014MonalizumabNKG2ANovoNordiskAgreementMember2021-12-310001598599Inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember2022-01-012022-01-310001598599Inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember2017-07-310001598599Inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember2020-10-012020-10-310001598599Inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember2018-08-012022-06-300001598599Inpha:IPH5401AntiC5aRRightsAcquiredFromNovoNordiskASMember2022-06-300001598599IFRS-Full:LandAndBuildingsMembers2020-12-310001598599Inpha:实验室设备和其他成员2020-12-310001598599IFRS-FULL:施工进度成员2020-12-310001598599Inpha:AssetsUnderFinanceLeaseAgreement成员2020-12-310001598599IFRS-Full:LandAndBuildingsMembers2021-01-012021-06-300001598599Inpha:实验室设备和其他成员2021-01-012021-06-300001598599IFRS-FULL:施工进度成员2021-01-012021-06-300001598599Inpha:AssetsUnderFinanceLeaseAgreement成员2021-01-012021-06-300001598599IFRS-Full:LandAndBuildingsMembers2021-06-300001598599Inpha:实验室设备和其他成员2021-06-300001598599IFRS-FULL:施工进度成员2021-06-300001598599Inpha:AssetsUnderFinanceLeaseAgreement成员2021-06-300001598599IFRS-Full:LandAndBuildingsMembers2021-12-310001598599Inpha:实验室设备和其他成员2021-12-310001598599IFRS-FULL:施工进度成员2021-12-310001598599IFRS-Full:RightofuseAssetsMember2021-12-310001598599IFRS-Full:LandAndBuildingsMembers2022-01-012022-06-300001598599Inpha:实验室设备和其他成员2022-01-012022-06-300001598599IFRS-FULL:施工进度成员2022-01-012022-06-300001598599IFRS-Full:RightofuseAssetsMember2022-01-012022-06-300001598599IFRS-Full:LandAndBuildingsMembers2022-06-300001598599Inpha:实验室设备和其他成员2022-06-300001598599IFRS-FULL:施工进度成员2022-06-300001598599IFRS-Full:RightofuseAssetsMember2022-06-300001598599Inpha:PGELoanaccesementSocieteGeneral成员2021-12-310001598599Inpha:PGELoanaccesementSocieteGeneral成员2022-01-012022-06-300001598599Inpha:PGELoanaccesementSocieteGeneral成员2022-06-300001598599Inpha:PGE贷款协议BNPParibasMember2021-12-310001598599Inpha:PGE贷款协议BNPParibasMember2022-01-012022-06-300001598599Inpha:PGE贷款协议BNPParibasMember2022-06-300001598599Inpha:LeaseFinancingObligationsBuildingLeVirageMember2021-12-310001598599Inpha:LeaseFinancingObligationsBuildingLeVirageMember2022-01-012022-06-300001598599Inpha:LeaseFinancingObligationsBuildingLeVirageMember2022-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMember2021-12-310001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMember2022-01-012022-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMember2022-06-300001598599Inpha:LeaseFinancingObligationsEquipmentMember2021-12-310001598599Inpha:LeaseFinancingObligationsEquipmentMember2022-01-012022-06-300001598599Inpha:LeaseFinancingObligationsEquipmentMember2022-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员2021-12-310001598599Inpha:LeaseFinancingObligationsVehicles成员2022-01-012022-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员2022-06-300001598599Inpha:LeaseFinancingObligationsPrintersMember2021-12-310001598599Inpha:LeaseFinancingObligationsPrintersMember2022-01-012022-06-300001598599Inpha:LeaseFinancingObligationsPrintersMember2022-06-300001598599Inpha:LoanEquipmentMember2021-12-310001598599Inpha:LoanEquipmentMember2022-01-012022-06-300001598599Inpha:LoanEquipmentMember2022-06-300001598599Inpha:LoanBuildingMember2021-12-310001598599Inpha:LoanBuildingMember2022-01-012022-06-300001598599Inpha:LoanBuildingMember2022-06-300001598599字母:BPIFrancePTZIIPH41成员2020-12-310001598599字母:BPIFrancePTZIIPH41成员2021-01-012021-06-300001598599字母:BPIFrancePTZIIPH41成员2021-06-300001598599Inpha:LeaseFinancingObligationsRealEstatePropertyMember2020-12-310001598599Inpha:LeaseFinancingObligationsRealEstatePropertyMember2021-01-012021-06-300001598599Inpha:LeaseFinancingObligationsRealEstatePropertyMember2021-06-300001598599Inpha:LeaseFinancingObligationsBuildingLeVirageMember2020-12-310001598599Inpha:LeaseFinancingObligationsBuildingLeVirageMember2021-01-012021-06-300001598599Inpha:LeaseFinancingObligationsBuildingLeVirageMember2021-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMember2020-12-310001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMember2021-01-012021-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMember2021-06-300001598599Inpha:LeaseFinancingObligationsEquipmentMember2020-12-310001598599Inpha:LeaseFinancingObligationsEquipmentMember2021-01-012021-06-300001598599Inpha:LeaseFinancingObligationsEquipmentMember2021-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员2020-12-310001598599Inpha:LeaseFinancingObligationsVehicles成员2021-01-012021-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员2021-06-300001598599Inpha:LeaseFinancingObligationsPrintersMember2020-12-310001598599Inpha:LeaseFinancingObligationsPrintersMember2021-01-012021-06-300001598599Inpha:LeaseFinancingObligationsPrintersMember2021-06-300001598599Inpha:LoanEquipmentMember2020-12-310001598599Inpha:LoanEquipmentMember2021-01-012021-06-300001598599Inpha:LoanEquipmentMember2021-06-300001598599Inpha:LoanBuildingMember2020-12-310001598599Inpha:LoanBuildingMember2021-01-012021-06-300001598599Inpha:LoanBuildingMember2021-06-300001598599Inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember2022-01-05Inpha:贷款协议0001598599Inpha:PGELoanaccesementSocieteGeneral成员2022-01-050001598599Inpha:PGE贷款协议BNPParibasMember2022-01-050001598599Inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember2022-01-052022-01-050001598599Inpha:带SocitGnraleMember的贷款协议2017-07-030001598599Inpha:带SocitGnraleMember的贷款协议2018-12-310001598599Inpha:带SocitGnraleMember的贷款协议2019-12-310001598599Inpha:带SocitGnraleMember的贷款协议2019-08-302019-08-300001598599Inpha:带SocitGnraleMember的贷款协议2022-06-300001598599Inpha:带SocitGnraleMember的贷款协议2017-07-032017-07-030001598599Inpha:带SocitGnraleMember的贷款协议IFRS-FULL:固定利率成员2022-06-300001598599IFRS-Full:不晚于一年成员Inpha:PGELoanaccesementSocieteGeneral成员2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberInpha:PGELoanaccesementSocieteGeneral成员2022-06-300001598599IFRS-Full:晚于五年成员Inpha:PGELoanaccesementSocieteGeneral成员2022-06-300001598599IFRS-Full:不晚于一年成员Inpha:PGE贷款协议BNPParibasMember2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberInpha:PGE贷款协议BNPParibasMember2022-06-300001598599IFRS-Full:晚于五年成员Inpha:PGE贷款协议BNPParibasMember2022-06-300001598599IFRS-Full:不晚于一年成员Inpha:LeaseFinancingObligationsBuildingLeVirageMember2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberInpha:LeaseFinancingObligationsBuildingLeVirageMember2022-06-300001598599IFRS-Full:晚于五年成员Inpha:LeaseFinancingObligationsBuildingLeVirageMember2022-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMemberIFRS-Full:不晚于一年成员2022-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMemberIfrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember2022-06-300001598599Inpha:LeaseFinancingObligationsInnateIncPremisesMemberIFRS-Full:晚于五年成员2022-06-300001598599IFRS-Full:不晚于一年成员Inpha:LeaseFinancingObligationsEquipmentMember2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberInpha:LeaseFinancingObligationsEquipmentMember2022-06-300001598599IFRS-Full:晚于五年成员Inpha:LeaseFinancingObligationsEquipmentMember2022-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员IFRS-Full:不晚于一年成员2022-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember2022-06-300001598599Inpha:LeaseFinancingObligationsVehicles成员IFRS-Full:晚于五年成员2022-06-300001598599IFRS-Full:不晚于一年成员Inpha:LeaseFinancingObligationsPrintersMember2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberInpha:LeaseFinancingObligationsPrintersMember2022-06-300001598599IFRS-Full:晚于五年成员Inpha:LeaseFinancingObligationsPrintersMember2022-06-300001598599IFRS-Full:不晚于一年成员Inpha:LoanEquipmentMember2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMemberInpha:LoanEquipmentMember2022-06-300001598599IFRS-Full:晚于五年成员Inpha:LoanEquipmentMember2022-06-300001598599Inpha:LoanBuildingMemberIFRS-Full:不晚于一年成员2022-06-300001598599Inpha:LoanBuildingMemberIfrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember2022-06-300001598599Inpha:LoanBuildingMemberIFRS-Full:晚于五年成员2022-06-300001598599IFRS-Full:不晚于一年成员2022-06-300001598599Ifrs-full:LaterThanTwoYearsAndNotLaterThanFiveYearsMember2022-06-300001598599IFRS-Full:晚于五年成员2022-06-300001598599Inpha:RetirementDefinedBenefitMember2022-06-300001598599Inpha:RetirementDefinedBenefitMember2021-12-310001598599Inpha:老年人奖成员2022-06-300001598599Inpha:老年人奖成员2021-12-310001598599Ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember2020-12-310001598599Ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember2020-12-310001598599IFRS-FULL:普通共享成员2022-06-300001598599Inpha:2016Free PferredShares成员2022-06-300001598599Inpha:2017Free PferredSharesMember2022-06-300001598599Inpha:BSAAR2012年成员2022-01-012022-06-300001598599Inpha:CompanySavingPlanMember2022-01-012022-06-300001598599Inpha:CompanySavingPlanEmployerTopUpMember2022-01-012022-06-300001598599首发:AGANewMembers 20171成员2022-01-012022-06-300001598599Inpha:BSAAR2012年成员2022-06-300001598599Inpha:CompanySavingPlanEmployeeContributionMember2022-01-012022-06-300001598599Inpha:CompanySavingPlanEmployeeContributionMember2022-06-300001598599Inpha:BSAAR2011年成员2021-06-302021-06-300001598599Inpha:BSAAR2011年成员2022-06-300001598599Inpha:BSAAR2012年成员2021-06-302021-06-300001598599Inpha:BSAAR2015成员2021-06-302021-06-300001598599Inpha:BSAAR2015成员2022-06-300001598599Inpha:AGAPManagement20161成员2021-06-302021-06-300001598599Inpha:AGAPManagement20161成员2022-06-300001598599首页:AGAP员工20161成员2021-06-302021-06-300001598599首页:AGAP员工20161成员2022-06-300001598599公司名称:AGA管理层20161成员2021-06-302021-06-300001598599公司名称:AGA管理层20161成员2022-06-300001598599Inpha:AGAPManagement20162成员2021-06-302021-06-300001598599Inpha:AGAPManagement20162成员2022-06-300001598599公司名称:AGA管理层20162成员2021-06-302021-06-300001598599公司名称:AGA管理层20162成员2022-06-300001598599Inpha:AGAP员工20171成员2021-06-302021-06-300001598599Inpha:AGAP员工20171成员2022-06-300001598599Inpha:AGAPManagement20171成员2021-06-302021-06-300001598599Inpha:AGAPManagement20171成员2022-06-300001598599Inpha:AGA员工2017年2021-06-302021-06-300001598599Inpha:AGA员工2017年2022-06-300001598599Inpha:AGABonus 20181成员2021-06-302021-06-300001598599Inpha:AGABonus 20181成员2022-06-300001598599Inpha:AGAPPerfEmployees20181成员2021-06-302021-06-300001598599Inpha:AGAPPerfEmployees20181成员2022-06-300001598599Inpha:AGAPPerfManagement 20181成员2021-06-302021-06-300001598599Inpha:AGAPPerfManagement 20181成员2022-06-300001598599Inpha:AGA员工2018年成员2021-06-302021-06-300001598599Inpha:AGA员工2018年成员2022-06-300001598599首发:AGANewMembers 20171成员2021-06-302021-06-300001598599首发:AGANewMembers 20171成员2022-06-300001598599首字母:AGABonus 20191成员2021-06-302021-06-300001598599首字母:AGABonus 20191成员2022-06-300001598599Inpha:AGABonus 20201成员2021-06-302021-06-300001598599Inpha:AGABonus 20201成员2022-06-300001598599Inpha:AGAPEmployees 20201成员2021-06-302021-06-300001598599Inpha:AGAPEmployees 20201成员2022-06-300001598599Inpha:AGAPManagement20201成员2021-06-302021-06-300001598599Inpha:AGAPManagement20201成员2022-06-300001598599Inpha:AGABonus 20211成员2021-06-302021-06-300001598599Inpha:AGABonus 20211成员2022-06-300001598599Inpha:AGAP员工20211名成员2021-06-302021-06-300001598599Inpha:AGAP员工20211名成员2022-06-300001598599Inpha:AGAPManagement20211成员2021-06-302021-06-300001598599Inpha:AGAPManagement20211成员2022-06-300001598599Inpha:StockOptions20201成员2021-06-302021-06-300001598599Inpha:StockOptions20201成员2022-06-300001598599首页:AGAP2019员工2019成员2021-06-302021-06-300001598599首页:AGAP2019员工2019成员2022-06-300001598599首页:AGAP2019管理层2019成员2021-06-302021-06-300001598599首页:AGAP2019管理层2019成员2022-06-300001598599Inpha:BSA20112成员2021-06-302021-06-300001598599Inpha:BSA20112成员2022-06-300001598599Inpha:BSA2013成员2021-06-302021-06-300001598599Inpha:BSA2013成员2022-06-300001598599Inpha:BSA2014成员2021-06-302021-06-300001598599Inpha:BSA2014成员2022-06-300001598599Inpha:BSA20151成员2021-06-302021-06-300001598599Inpha:BSA20151成员2022-06-300001598599Inpha:BSA20152成员2021-06-302021-06-300001598599Inpha:BSA20152成员2022-06-300001598599Inpha:BSA2017成员2021-06-302021-06-300001598599Inpha:BSA2017成员2022-06-300001598599Inpha:质保人成员2021-06-302021-06-300001598599Inpha:质保人成员2022-06-300001598599Inpha:非当前财务资产成员2022-06-300001598599Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberInpha:非当前财务资产成员2022-06-300001598599Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberInpha:非当前财务资产成员2022-06-300001598599Inpha:贸易应收账款和其他成员2022-06-300001598599Inpha:贸易应收账款和其他成员Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Inpha:贸易应收账款和其他成员Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2022-06-300001598599Inpha:ShortTermInvestments成员2022-06-300001598599Inpha:ShortTermInvestments成员Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Inpha:ShortTermInvestments成员Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2022-06-300001598599Inpha:现金和现金等价物成员2022-06-300001598599Inpha:现金和现金等价物成员Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Inpha:现金和现金等价物成员Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2022-06-300001598599Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2022-06-300001598599Inpha:FinancialLiabilitiesNonCurrentPortionMember2022-06-300001598599Inpha:FinancialLiabilitiesNonCurrentPortionMemberIfrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberInpha:FinancialLiabilitiesNonCurrentPortionMember2022-06-300001598599Inpha:FinancialLiabilitiesCurrentPortionMember2022-06-300001598599Inpha:FinancialLiabilitiesCurrentPortionMemberIfrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Inpha:FinancialLiabilitiesCurrentPortionMemberIfrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2022-06-300001598599Inpha:TradePayablesAndOthersMembers2022-06-300001598599Ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberInpha:TradePayablesAndOthersMembers2022-06-300001598599Ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberInpha:TradePayablesAndOthersMembers2022-06-300001598599Ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2022-06-300001598599Ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2022-06-300001598599Inpha:非当前财务资产成员2021-12-310001598599Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberInpha:非当前财务资产成员2021-12-310001598599Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberInpha:非当前财务资产成员2021-12-310001598599Inpha:贸易应收账款和其他成员2021-12-310001598599Inpha:贸易应收账款和其他成员Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Inpha:贸易应收账款和其他成员Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-12-310001598599Inpha:ShortTermInvestments成员2021-12-310001598599Inpha:ShortTermInvestments成员Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Inpha:ShortTermInvestments成员Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-12-310001598599Inpha:现金和现金等价物成员2021-12-310001598599Inpha:现金和现金等价物成员Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Inpha:现金和现金等价物成员Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-12-310001598599Ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2021-12-310001598599Inpha:FinancialLiabilitiesNonCurrentPortionMember2021-12-310001598599Inpha:FinancialLiabilitiesNonCurrentPortionMemberIfrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberInpha:FinancialLiabilitiesNonCurrentPortionMember2021-12-310001598599Inpha:FinancialLiabilitiesCurrentPortionMember2021-12-310001598599Inpha:FinancialLiabilitiesCurrentPortionMemberIfrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Inpha:FinancialLiabilitiesCurrentPortionMemberIfrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-12-310001598599Inpha:TradePayablesAndOthersMembers2021-12-310001598599Ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberInpha:TradePayablesAndOthersMembers2021-12-310001598599Ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberInpha:TradePayablesAndOthersMembers2021-12-310001598599Ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2021-12-310001598599Ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2021-12-310001598599Inpha:CollaborationAndLicensingAgreementsMember2022-01-012022-06-300001598599Inpha:CollaborationAndLicensingAgreementsMember2021-01-012021-06-300001598599Inpha:MonalizumabGonementMember2021-01-012021-06-300001598599Inpha:A2018AstraZenecaIPH5201协议成员2022-01-012022-06-300001598599Inpha:A2018AstraZenecaIPH5201协议成员2021-01-012021-06-300001598599Inpha:PreclinicalMoleculesAgreementWithAstraZenecaMember2022-01-012022-06-300001598599Inpha:PreclinicalMoleculesAgreementWithAstraZenecaMember2021-01-012021-06-300001598599Inpha:AgreementRelatedToIPH6101WithSanofiMember2021-01-012021-06-300001598599初始:其他协议成员2022-01-012022-06-300001598599初始:其他协议成员2021-01-012021-06-300001598599Inpha:IPH5201AndAdvoralimabAgreement成员2022-01-012022-06-300001598599Inpha:IPH5201AndAdvoralimabAgreement成员2021-01-012021-06-300001598599Inpha:协作协议成员2022-01-012022-06-300001598599Inpha:协作协议成员2021-01-012021-06-300001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMemberInpha:递延收入成员2020-12-310001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMemberInpha:递延收入成员2021-01-012021-06-300001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMemberInpha:递延收入成员2021-06-300001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMemberInpha:递延收入成员2021-12-310001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMemberInpha:递延收入成员2022-01-012022-06-300001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMemberInpha:递延收入成员2022-06-300001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2022-06-172022-06-170001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2020-12-310001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2021-01-012021-06-300001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2021-06-300001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2021-12-310001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2022-01-012022-06-300001598599Inpha:协作责任成员Inpha:A2015AstraZenecaMonalizumabAgreementsMember2022-06-300001598599Inpha:IPH43IPH25IPH26AndIPH62WithAstraZenecaMember2022-06-020001598599Inpha:IPH43IPH25IPH26AndIPH62WithAstraZenecaMemberInpha:递延收入成员2020-12-310001598599Inpha:IPH43IPH25IPH26AndIPH62WithAstraZenecaMemberInpha:递延收入成员2021-01-012021-06-300001598599Inpha:IPH43IPH25IPH26AndIPH62WithAstraZenecaMemberInpha:递延收入成员2021-06-300001598599Inpha:MonalizumabMemberInpha:递延收入成员2021-12-310001598599Inpha:MonalizumabMemberInpha:递延收入成员2022-01-012022-06-300001598599Inpha:MonalizumabMemberInpha:递延收入成员2022-06-300001598599Inpha:IPH5201成员Inpha:递延收入成员2021-12-310001598599Inpha:IPH5201成员Inpha:递延收入成员2022-01-012022-06-300001598599Inpha:IPH5201成员Inpha:递延收入成员2022-06-300001598599Inpha:临床前分子成员Inpha:递延收入成员2021-12-310001598599Inpha:临床前分子成员Inpha:递延收入成员2022-01-012022-06-300001598599Inpha:临床前分子成员Inpha:递延收入成员2022-06-300001598599Inpha:其他成员Inpha:递延收入成员2021-12-310001598599Inpha:其他成员Inpha:递延收入成员2022-01-012022-06-300001598599Inpha:其他成员Inpha:递延收入成员2022-06-300001598599Inpha:递延收入成员2021-12-310001598599Inpha:递延收入成员2022-01-012022-06-300001598599Inpha:递延收入成员2022-06-300001598599Inpha:MonalizumabMemberInpha:递延收入成员2020-12-310001598599Inpha:MonalizumabMemberInpha:递延收入成员2021-01-012021-06-300001598599Inpha:MonalizumabMemberInpha:递延收入成员2021-06-300001598599Inpha:IPH5201成员Inpha:递延收入成员2020-12-310001598599Inpha:IPH5201成员Inpha:递延收入成员2021-01-012021-06-300001598599Inpha:IPH5201成员Inpha:递延收入成员2021-06-300001598599Inpha:临床前分子成员Inpha:递延收入成员2020-12-310001598599Inpha:临床前分子成员Inpha:递延收入成员2021-01-012021-06-300001598599Inpha:临床前分子成员Inpha:递延收入成员2021-06-300001598599Inpha:递延收入成员2020-12-310001598599Inpha:递延收入成员2021-01-012021-06-300001598599Inpha:递延收入成员2021-06-300001598599Inpha:BPIFranceCovid19Program成员2021-01-012021-06-300001598599IFRS-Full:运营部门成员Inpha:研究和开发成员2022-01-012022-06-300001598599IFRS-Full:运营部门成员Inpha:销售总成和管理成员2022-01-012022-06-300001598599IFRS-Full:运营部门成员Inpha:研究和开发成员2021-01-012021-06-300001598599IFRS-Full:运营部门成员Inpha:销售总成和管理成员2021-01-012021-06-300001598599SRT:情景预测成员2022-01-012022-12-310001598599IFRS-FULL:停产运营成员2022-01-012022-06-300001598599IFRS-FULL:停产运营成员2021-01-012021-06-300001598599Inpha:临床前工作成员2022-06-300001598599Inpha:ClinicalWorkMember2022-06-300001598599Inpha:IPH5201AntiCD39RightsAcquiredFromOregaBiotechMember2022-01-012022-06-300001598599Inpha:NovoNordiskASMember2022-06-30Inpha:许可协议0001598599Inpha:MiMAbsMember2021-02-022021-02-020001598599Inpha:MiMAbsMember2021-12-172021-12-170001598599Inpha:MiMAbsMember2022-04-042022-04-040001598599Inpha:A2015AstraZenecaMonalizumabAgreementsMember2020-09-300001598599Inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember2022-01-050001598599Inpha:PGELoanaccesementSocieteGeneral成员2022-01-050001598599Inpha:PGE贷款协议BNPParibasMember2022-01-050001598599Inpha:PGELoanAgreementSocieteGeneraleAndBNPParibasMember2022-01-052022-01-050001598599Inpha:PGELoanaccesementSocieteGeneral成员首字母:主要贷款融资成员2022-09-150001598599Inpha:PGE贷款协议BNPParibasMember首字母:主要贷款融资成员2022-09-15



美国
美国证券交易委员会
华盛顿特区20549表格6-K
外国私人发行人根据1934年《证券交易法》第13a-16条或15d-16条提交的报告

报告日期:2022年9月15日
委托公文编号:001-39084
先天医药公司
(注册人姓名英文译本)

先天医药公司
灯塔大道117号-BP 30191
13009马赛,法国
+ 33 (0) 4 30 30 30
(主要行政办公室地址)

用复选标记表示注册人是否在20-F或40-F表格的封面下提交或将提交年度报告。表格20-F[ X ] Form 40-F []
用复选标记表示注册人是否按照S-T规则101(B)(1)所允许的纸质形式提交了表格6-K:[]
用复选标记表示注册人是否按照S-T规则101(B)(7)所允许的纸质形式提交表格6-K:[]

以引用方式成立为法团
这份表格6-K的报告以及本报告的表格6-K的附件99.1和99.2应被视为通过引用的方式并入固有制药公司表格F-3的注册声明(文件编号333-252074)和表格S-8的注册声明(文件编号333-233865)中(包括构成该等注册声明的任何招股说明书),并自提交本报告之日起成为注册声明的一部分,但不得被随后提交或提交的文件或报告所取代。




展品索引

展品


99.1新闻稿日期:2022年9月15日
99.2 2021年上半年财务报告,2022年1月1日至6月30日





签名

根据1934年《证券交易法》的要求,注册人已正式促使本报告由正式授权的签署人代表其签署。

先天制药公司


日期:2022年9月15日:/s/Mondher Mahjoubi姓名:Mondher Mahjoubi
头衔:首席执行官